Hemostatic biomarkers in dogs with chronic congestive heart failure

Journal of Veterinary Internal Medicine

Volumn 21, Issue 3, 2007, Pages 451-457

  Tarnow, Inge ^a   Falk, Torkel ^a   Tidholm, Anna ^b   Martinussen, Torben ^a   Jensen, Asger L ^a   Olsen, Lisbeth H ^a   Pedersen, Henrik D ^c   Kristensen, Annemarie T ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Albano Djursjukhus ^*  (Sweden)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Chronic valvular disease; Coagulation; Dilated cardiomyopathy; Thrombosis

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; FIBRINOGEN; PEPTIDE HYDROLASE; PROTEIN C; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CASE CONTROL STUDY; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; DOG; DOG DISEASE; ECHOCARDIOGRAPHY; FEMALE; HOSPITALIZATION; MALE; METABOLISM; METHODOLOGY; MORTALITY; PREDICTION AND FORECASTING; PROGNOSIS;

ANIMALS; ANTITHROMBIN III; ANTITHROMBINS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHRONIC DISEASE; DOG DISEASES; DOGS; ECHOCARDIOGRAPHY; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HEART FAILURE, CONGESTIVE; MALE; PEPTIDE HYDROLASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN C; SEVERITY OF ILLNESS INDEX;

ANIMALIA; CANIS FAMILIARIS;

EID: 34249335664     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2007)21[451:HBIDWC]2.0.CO;2     Document Type: Article

References (47)

1. Boswood A, Attree S, Page K. Clinical validation of a proANP 31-67 fragment ELISA in the diagnosis of heart failure in the dog. J Small Anim Pract 2003;44:104-108.
2. MacDonald KA, Kittleson MD, Munro C, Kass P. Brain natriuretic peptide concentration in dogs with heart disease and congestive heart failure. J Vet Intern Med 2003;17:172-177.
3. Ware WA, Lund DD, Subieta AR, Schmid PG. Sympathetic activation in dogs with congestive heart failure caused by chronic mitral valve disease and dilated cardiomyopathy. J Am Vet Med Assoc 1990;197:1475-1481.
4. Borgarelli M, Badino P, Bergamasco L, et al. Lymphocyte beta-adrenoceptor downregulation in Great Danes with occult dilated cardiomyopathy (DCM) and with DCM and heart failure. Vet J 1999;158:128-134.
5. Tidholm A, Haggstrom J, Hansson K. Vasopressin, cortisol, and catecholamine concentrations in dogs with dilated cardiomyopathy. Am J Vet Res 2005;66:1709-1717.
6. Prosek R, Sisson DD, Oyama MA, et al. Plasma endothelin-1 immunoreactivity in normal dogs and dogs with acquired heart disease. J Vet Intern Med 2004;18:840-844.
7. Spratt DP, Mellanby RJ, Drury N, Archer J. Cardiac troponin I: Evaluation I of a biomarker for the diagnosis of heart disease in the dog. J Small Anim Pract 2005;46:139-145.
8. Oyama MA, Sisson DD. Cardiac troponin-I concentration in dogs with cardiac disease. J Vet Intern Med 2004;18:831-839.
9. Greco DS, Biller B, Van Liew CH. Measurement of plasma atrial natriuretic peptide as an indicator of prognosis in dogs with cardiac disease. Can Vet J 2003;44:293-297.
10. De Lorenzo F, Saba N, Kakkar W. Blood coagulation in patients with chronic heart failure: Evidence for hypercoagulable state and potential for pharmacological intervention. Drugs 2003;63:565-576.
11. Davis CJ, Gurbel PA, Gattis WA, et al. Hemostatic abnormalities in patients with congestive heart failure: Diagnostic significance and clinical challenge. Int J Cardiol 2000;75:15-21.
12. Marcucci R, Gori AM, Giannotti F, et al. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost 2006;4:1017-1022.
13. Yusuf S. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
14. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-1552.
15. Corcoran BM, Black A, Anderson H, et al. Identification of surface morphologic changes in the mitral valve leaflets and chordae tendineae of dogs with myxomatous degeneration. Am J Vet Res 2004;65:198-206.
16. Johnson LR, Lappin MR, Baker DC. Pulmonary thromboembolism in 29 dogs: 1985-1995. J Vet Intern Med 1999;13:338-345.
17. Larue MJ, Murtaugh RJ. Pulmonary thromboembolism in dogs: 47 cases (1986-1987). J Am Vet Med Assoc 1990;197:1368-1372.
18. Palmer KG, King LG, Van Winkle TJ. Clinical manifestations and associated disease syndromes in dogs with cranial vena cava thrombosis: 17 cases (1989-1996). J Am Vet Med Assoc 1998;213:220-224.
19. Kvart C, Haggstrom J, Pedersen HD, et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet Intern Med 2002;16:80-88.
20. Hansson K, Haggstrom J, Kvart C, Lord P. Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in Cavalier King Charles Spaniels with and without left atrial enlargement. Vet Radiol Ultrasound 2002;43:568-575.
21. Kjelgaard-Hansen M, Jensen AL, Kristensen AT. Evaluation of a commercially available human C-reactive protein (CRP) turbidometric immunoassay for determination of canine serum CRP concentration. Vet Clin Pathol 2003;32:81-87.
22. Cornell CC, Kittleson MD, Torre PD, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004;18:311-321.
23. Cox DR. Regression models and life tables. J R Stat Soc [Ser B] 1972;34:187-220.
24. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993; 80(3):557-572.
25. Ravanat C, Freund M, Dol F, et al. Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species. Blood Coagul Fibrinolysis 1995;6:446-455.
26. Chen L, Nichols WW, Mattsson C, et al. Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. J Pharmacol Exp Ther 1996;277:1276-1283.
27. Nicolini FA, Lee P, Malycky JL, et al. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul Fibrinolysis 1996;7:39-48.
28. Nelson OL, Andreasen C. The utility of plasma D-dimer to identify thromboembolic disease in dogs. J Vet Intern Med 2003;17:830-834.
29. Griffin A, Callan MB, Shofer FS, Giger U. Evaluation of a canine D-dimer point-of-care test kit for use in samples obtained from dogs with disseminated intravascular coagulation, thromboembolic disease, and hemorrhage. Am J Vet Res 2003;64:1562-1569.
30. Jafri SM, Ozawa T, Mammen E, et al. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993;14:205-212.
31. Sbarouni E, Bradshaw A, Andreotti F, et al. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994;127:607-612.
32. Cugno M, Mari D, Meroni PL, et al. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: Role of oral anticoagulants and successful heart transplantation. Br J Haematol 2004;126:85-92.
33. Jafri SM. Hypercoagulability in heart failure. Semin Thromb Hemost 1997;23:543-545.
34. de Laforcade AM, Freeman LM, Shaw SP, et al. Hemostatic changes in dogs with naturally occurring sepsis. J Vet Intern Med 2003;17:674-679.
35. Mischke R, Wohlsein P, Busse L, Pohlenz J. Disseminated intravascular coagulation and hyperfibrinolysis in dogs with metastasizing mammary carcinoma. Schweiz Arch Tierheilkd 1998;140:497-505.
36. Caprini JA, Glase CJ, Anderson CB, Hathaway K. Laboratory markers in the diagnosis of venous thromboembolism. Circulation 2004; 109:14-18.
37. Mischke R. Acute haemostatic changes in accidentally traumatised dogs. Vet J 2005;169:60-64.
38. Johnstone IB, Martin CA. Comparative effects of the human protein C activator, Protac, on the activated partial thromboplastin clotting times of plasmas, with special reference to the dog. Can J Vet Res 2000;64:117-122.
39. Palsgaard-Van Lue A, Jensen AL, Strom H, Kristensen AT. Comparative analysis of haematological, haemostatic, and inflammatory parameters in canine venous and arterial blood samples. Vet J 2006. In press.
40. Rush JE, Lee ND, Freeman LM, Brewer B. C-reactive protein concentration in dogs with chronic valvular disease. J Vet Intern Med 2006;20:635-639.
41. Patterson DF, Detweiler DK, Hubben K, Botts RP. Spontaneous abnormal cardiac arrhythmias and conduction disturbances in the dog: A clinical and pathologic study of 3,000 dogs. Am J Vet Res 1961;22:355-369.
42. Falk T, Jonsson L, Olsen LH, Pedersen HD. Arteriosclerotic changes in the myocardium, lung, and kidney in dogs with chronic congestive heart failure and myxomatous mitral valve disease. Cardiovasc Pathol 2006;15:185-193.
43. Falk T, Jonsson L. Ischaemic heart disease in the dog: A review of 65 cases. J Small Anim Pract 2000;41:97-103.
44. Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure: A request and proposition for more accurate classification. Eur Heart J 1996;17:1390-1403.
45. Tarnow I, Kristensen AT, Olsen LH, Pedersen HD. Assessment of changes in hemostatic markers in Cavalier King Charles Spaniels with myxomatous mitral valve disease. Am J Vet Res 2004;65:1644-1652.
46. Hughes R, Thomson K, Hopkins R, et al. Determinants of plasma D-dimer levels in a traveling population. J Thromb Haemost 2005;3:2445-2448.
47. Dolan G, Neal K, Cooper P, et al. Protein C, antithrombin III and plasminogen: Effect of age, sex and blood group. Br J Haematol 1994;86:798-803.